immunoglobulin G + acetylsalicylic acid

**immunoglobulin G + acetylsalicylic acid** is a combination of intravenous immunoglobulin G (IVIG) and acetylsalicylic acid (aspirin) primarily used for the acute-phase treatment of **Kawasaki disease (KD)** in pediatric populations. IVIG is a polyvalent antibody therapy derived from pooled human plasma, exerting its effects via immune modulation, neutralization of pathogenic antigens, and anti-inflammatory pathways. Acetylsalicylic acid is a non-steroidal anti-inflammatory drug (NSAID) with both anti-inflammatory and antiplatelet properties, inhibiting cyclooxygenase enzymes that mediate prostaglandin and thromboxane synthesis[1][3][4][5]. In treatment protocols, IVIG (typically a single dose of 2 g/kg) is administered intravenously, and acetylsalicylic acid is provided at either high (80-100 mg/kg/day) or low (3-5 mg/kg/day) oral doses, depending on the clinical phase and guidelines. The mechanism of IVIG involves broad suppression of immune-mediated vasculitis and attenuation of inflammatory cytokines, while acetylsalicylic acid serves to diminish inflammation and, at lower doses, reduce thrombosis risk. Recent randomized controlled trials and meta-analyses suggest that the **addition of high-dose aspirin to IVIG does not confer additional clinical benefit over IVIG alone in reducing coronary artery lesions** in KD[1][3][4][5]. This combination is not a branded or uniquely formulated product, but rather a protocol utilizing two established agents, both widely manufactured and distributed by multiple companies.

Other names

IVIG + aspirinintravenous immunoglobulin + acetylsalicylic acid